StemCell Institute AI Stock Analysis
Want to see JP:7096 full AI Analyst Report?
StemCell Institute (7096) AI Stock Analysis
StemCell Institute
(TSE/TYO:7096)
The overall score reflects significant near-term headwinds. The most impactful risks are the company's severe margin compression, accelerating cash burn, and an expensive P/E ratio of 57.5x without dividend support. Technical analysis corroborates this weakness, revealing a strong bearish trend with shares trading below all key moving averages. While the company's low-debt balance sheet provides a crucial safety net against insolvency, it is currently overshadowed by operational and market momentum pressures.
StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 5,133
- Price to Earnings (P/E)
- 55.8
- Beta (1Y)
- 0.52
- Revenue Growth
- 2.55%
- EPS Growth
- -43.06%
- Country
- Japan
- Employees
- 117
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
StemCell Institute Business Overview & Revenue Model
Company Description
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, an...
StemCell Institute Financial Statement Overview
Summary
Financial performance is mixed, anchored by a highly defensive balance sheet with minimal debt and consistent top-line growth. However, this is significantly offset by severe operating margin compression and aggressively worsening negative free cash flow.
Income Statement
55NeutralBalance Sheet
85Very PositiveCash Flow
30Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.81B | 2.81B | 2.68B | 2.48B | 2.09B | 1.78B |
| Gross Profit | 1.71B | 1.71B | 1.69B | 1.58B | 1.34B | 1.11B |
| EBITDA | 368.87M | 379.99M | 695.19M | 534.00M | 402.49M | 309.47M |
| Net Income | 153.86M | 155.92M | 385.80M | 310.98M | 198.03M | 133.73M |
Balance Sheet | ||||||
| Total Assets | 8.12B | 8.12B | 7.52B | 6.59B | 5.83B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 2.83B | 3.20B | 2.85B | 3.32B | 3.51B |
| Total Debt | 473.81M | 473.81M | 518.96M | 10.78M | 5.89M | 0 |
| Total Liabilities | 5.05B | 5.05B | 4.89B | 3.90B | 3.53B | 3.13B |
| Stockholders Equity | 2.68B | 2.68B | 2.63B | 2.69B | 2.30B | 2.10B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -335.78M | -10.11M | 132.97M | 39.77M | 264.81M |
| Operating Cash Flow | 0 | 73.51M | 467.69M | 334.63M | 99.67M | 469.29M |
| Investing Cash Flow | 0 | -337.92M | -259.08M | -811.77M | -285.10M | 404.17M |
| Financing Cash Flow | 0 | -175.09M | 146.70M | -1.33M | -869.00K | 644.37M |
StemCell Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 640.00 is below the 20-day moving average (MA) of 675.80, below the 50-day MA of 714.50, and below the 200-day MA of 748.40, indicating a bearish trend. The MACD of -22.52 indicates Positive momentum. The RSI at 33.11 is Neutral, neither overbought nor oversold. The STOCH value of 20.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.
StemCell Institute Peers Comparison
Overall Rating
JP:709649Neutral
JP:497845Neutral
JP:777442Neutral
JP:459938Underperform
JP:459337Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | JPY 6.56B | 55.76 | ― | ― | 2.55% | -43.06% | |
| 45Neutral | JPY 11.75B | -24.37 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.03B | -70.96 | ― | ― | 17.05% | 10.47% | |
| 38Underperform | JPY 7.77B | -4.21 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 28.46B | -12.25 | ― | ― | -51.55% | 52.19% | |
| 37Underperform | JPY 6.07B | -4.74 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7096 | StemCell Institute | 640.00 | -124.00 | -16.23% | |
| JP:4593 | Healios KK | 210.00 | -265.00 | -55.79% | |
| JP:4599 | StemRIM Inc. | 124.00 | -154.00 | -55.40% | |
| JP:4978 | ReproCELL Inc. | 110.00 | -51.00 | -31.68% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 641.00 | 156.00 | 32.16% | |
| JP:7776 | CellSeed Inc. | 153.00 | -146.00 | -48.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
